(RGNX) Regenxbio - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 440m USD | Total Return: 43.8% in 12m

Gene Therapy, Drug Candidates, Technology Platform
Total Rating 25
Safety 41
Buy Signal -1.10
Biotechnology
Industry Rotation: +3.6
Market Cap: 440m
Avg Trading Vol: 5.87M USD
ATR: 7.64%
Peers RS (IBD): 8.8
Risk 5d forecast
Volatility79.4%
Rel. Tail Risk-7.45%
Reward TTM
Sharpe Ratio0.61
Alpha-2.04
Character TTM
Beta1.712
Beta Downside1.064
Drawdowns 3y
Max DD78.42%
CAGR/Max DD-0.29
EPS (Earnings per Share) EPS (Earnings per Share) of RGNX over the last years for every Quarter: "2021-03": -1.2, "2021-06": -1.36, "2021-09": -1.37, "2021-12": 6.67, "2022-03": -1.79, "2022-06": -1.58, "2022-09": -1.75, "2022-12": -1.38, "2023-03": -1.53, "2023-06": -1.66, "2023-09": -1.41, "2023-12": -1.43, "2024-03": -1.33, "2024-06": -1.05, "2024-09": -1.17, "2024-12": -1.01, "2025-03": 0.12, "2025-06": -1.38, "2025-09": -1.2, "2025-12": -1.3, "2026-03": 0,
EPS CAGR: 62.47%
EPS Trend: 59.3%
Last SUE: 1.72
Qual. Beats: 1
Revenue Revenue of RGNX over the last years for every Quarter: 2021-03: 18.884, 2021-06: 22.035, 2021-09: 30.773, 2021-12: 398.655, 2022-03: 22.218, 2022-06: 32.649, 2022-09: 26.512, 2022-12: 31.345, 2023-03: 19.138, 2023-06: 19.977, 2023-09: 28.914, 2023-12: 22.213, 2024-03: 15.622, 2024-06: 22.295, 2024-09: 24.197, 2024-12: 21.214, 2025-03: 89.012, 2025-06: 21.359, 2025-09: 29.733, 2025-12: 30.337, 2026-03: null,
Rev. CAGR: 8.66%
Rev. Trend: 18.7%
Last SUE: -1.79
Qual. Beats: 0
Warnings

volatile

Tailwinds

No distinct edge detected

Description: RGNX Regenxbio

REGENXBIO Inc. (RGNX) is a clinical-stage biotechnology company developing gene therapies in the United States. The companys therapies aim to correct genetic defects by delivering functional genes to cells, a common approach in gene therapy.

RGNX utilizes its proprietary NAV Technology Platform, an adeno-associated virus (AAV) gene delivery system. AAV vectors are frequently used in gene therapy due to their safety profile and ability to infect both dividing and non-dividing cells.

Key pipeline candidates include ABBV-RGX-314 for various retinal diseases and RGX-202, currently in Phase III for Duchenne muscular dystrophy. The company also develops treatments for mucopolysaccharidosis types I and II, and neuronal ceroid lipofuscinosis type 2.

RGNX licenses its NAV Technology Platform to other companies, indicating a dual business model of internal drug development and technology commercialization. A collaboration with AbbVie Global Enterprises Ltd. extends the development of ABBV-RGX-314 internationally. To gain deeper insights into RGNXs market position and financials, further research on ValueRay is recommended.

Headlines to Watch Out For
  • ABBV-RGX-314 clinical trial results impact future revenue
  • Regulatory approval for pipeline drugs crucial for commercialization
  • NAV Technology Platform licensing agreements drive recurring income
  • Duchenne muscular dystrophy drug trial success boosts valuation
Piotroski VR‑10 (Strict) 2.0
Net Income: -193.9m TTM > 0 and > 6% of Revenue
FCF/TA: -0.28 > 0.02 and ΔFCF/TA 9.78 > 1.0
NWC/Revenue: 95.74% < 20% (prev 209.8%; Δ -114.0% < -1%)
CFO/TA -0.27 > 3% & CFO -124.0m > Net Income -193.9m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 2.38 > 1.5 & < 3
Outstanding Shares: last quarter (51.8m) vs 12m ago 1.73% < -2%
Gross Margin: 52.88% > 18% (prev 0.50%; Δ 5.24k% > 0.5%)
Asset Turnover: 37.09% > 50% (prev 17.88%; Δ 19.21% > 0%)
Interest Coverage Ratio: -3.58 > 6 (EBITDA TTM -145.6m / Interest Expense TTM 45.0m)
Altman Z'' -11.47
A: 0.36 (Total Current Assets 281.3m - Total Current Liabilities 118.1m) / Total Assets 453.0m
B: -2.49 (Retained Earnings -1.13b / Total Assets 453.0m)
C: -0.35 (EBIT TTM -161.2m / Avg Total Assets 459.5m)
D: -3.22 (Book Value of Equity -1.13b / Total Liabilities 350.3m)
Altman-Z'' Score: -11.47 = D
Beneish M -2.69
DSRI: 0.60 (Receivables 26.4m/21.6m, Revenue 170.4m/83.3m)
GMI: 0.94 (GM 52.88% / 49.84%)
AQI: 1.22 (AQ_t 0.04 / AQ_t-1 0.04)
SGI: 2.05 (Revenue 170.4m / 83.3m)
TATA: -0.15 (NI -193.9m - CFO -124.0m) / TA 453.0m)
Beneish M-Score: -2.69 (Cap -4..+1) = A
What is the price of RGNX shares? As of April 06, 2026, the stock is trading at USD 8.53 with a total of 420,975 shares traded.
Over the past week, the price has changed by +9.78%, over one month by -2.18%, over three months by -36.34% and over the past year by +43.84%.
Is RGNX a buy, sell or hold? Regenxbio has received a consensus analysts rating of 4.42. Therefore, it is recommended to buy RGNX.
  • StrongBuy: 6
  • Buy: 5
  • Hold: 1
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the RGNX price?
Wallstreet Target Price 27.8 226.1%
Analysts Target Price 27.8 226.1%
RGNX Fundamental Data Overview as of 06 April 2026
P/S = 2.5831
P/B = 4.283
P/EG = 0.26
Revenue TTM = 170.4m USD
EBIT TTM = -161.2m USD
EBITDA TTM = -145.6m USD
Long Term Debt = 73.5m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 47.9m USD (from shortTermDebt, last quarter)
Debt = 260.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 226.1m USD (from netDebt column, last quarter)
Enterprise Value = 470.7m USD (440.3m + Debt 260.5m - CCE 230.1m)
Interest Coverage Ratio = -3.58 (Ebit TTM -161.2m / Interest Expense TTM 45.0m)
EV/FCF = -3.72x (Enterprise Value 470.7m / FCF TTM -126.4m)
FCF Yield = -26.85% (FCF TTM -126.4m / Enterprise Value 470.7m)
FCF Margin = -74.15% (FCF TTM -126.4m / Revenue TTM 170.4m)
Net Margin = -113.8% (Net Income TTM -193.9m / Revenue TTM 170.4m)
Gross Margin = 52.88% ((Revenue TTM 170.4m - Cost of Revenue TTM 80.3m) / Revenue TTM)
Gross Margin QoQ = 80.46% (prev -107.9%)
Tobins Q-Ratio = 1.04 (Enterprise Value 470.7m / Total Assets 453.0m)
Interest Expense / Debt = 4.71% (Interest Expense 12.3m / Debt 260.5m)
Taxrate = 21.0% (US default 21%)
NOPAT = -127.3m (EBIT -161.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.38 (Total Current Assets 281.3m / Total Current Liabilities 118.1m)
Debt / Equity = 2.54 (Debt 260.5m / totalStockholderEquity, last quarter 102.7m)
 Debt / EBITDA = -1.55 (negative EBITDA) (Net Debt 226.1m / EBITDA -145.6m)
 Debt / FCF = -1.79 (negative FCF - burning cash) (Net Debt 226.1m / FCF TTM -126.4m)
 Total Stockholder Equity = 188.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -42.19% (Net Income -193.9m / Total Assets 453.0m)
RoE = -103.1% (Net Income TTM -193.9m / Total Stockholder Equity 188.0m)
RoCE = -61.64% (EBIT -161.2m / Capital Employed (Equity 188.0m + L.T.Debt 73.5m))
 RoIC = -67.73% (negative operating profit) (NOPAT -127.3m / Invested Capital 188.0m)
 WACC = 8.92% (E(440.3m)/V(700.8m) * Re(12.0%) + D(260.5m)/V(700.8m) * Rd(4.71%) * (1-Tc(0.21)))
Discount Rate = 12.0% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 8.45%
 [DCF] Fair Price = unknown (Cash Flow -126.4m)
 EPS Correlation: 59.31 | EPS CAGR: 62.47% | SUE: 1.72 | # QB: 1
Revenue Correlation: 18.74 | Revenue CAGR: 8.66% | SUE: -1.79 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.10 | Chg7d=+0.382 | Chg30d=+0.542 | Revisions Net=-1 | Analysts=5
EPS current Year (2026-12-31): EPS=-2.00 | Chg7d=+0.220 | Chg30d=+0.179 | Revisions Net=-2 | Growth EPS=+46.8% | Growth Revenue=+49.9%
EPS next Year (2027-12-31): EPS=-2.20 | Chg7d=-0.316 | Chg30d=-0.213 | Revisions Net=+0 | Growth EPS=-9.9% | Growth Revenue=+19.7%
[Analyst] Revisions Ratio: -0.33 (1 Up / 2 Down within 30d for Next Quarter)
External Resources
Dataroma Stockcircle